Information Library
Results for: Clinical Services - Phase I/IIa
In the complex environment of the New Health, Quintiles is committed to helping you succeed. At every stage of your product’s lifecycle, we are dedicated to delivering real results, being proactive in navigating issues and thinking of new solutions. Search our library today.
- Sort by:
- Recently Added
- Title
-
Quintiles Wins Best CRO In Vaccine Excellence Awards 2012
Press Release — April 12, 2012 – Quintiles, the world’s leading global biopharmaceutical services company, announced that it has been named Best Clinical Research Organization (CRO) in the Vaccine Industry Excellence (ViE) Awards 2012.
-
American Diabetes Association to Collaborate with Quintiles’ Digital Patient Unit
Press Release — April 4, 2012 – Quintiles and the American Diabetes Association announced a strategic agreement in which Quintiles’ Digital Patient Unit will provide the Association’s millions of website users access to Quintiles’ medication monitoring service.
-
Cancer Treatments and the Search for Value
White Paper — April 2, 2012
Cancer Treatment and the Search for Value In September 2011, The Economist Intelligence Unit surveyed 399 senior executives from the life sciences industry and payer -
Accelerating Success in Oncology
Brochure — March 9, 2012
New Demands to Demonstrate Value Require New Strategy Proof of efficacy is no longer enough to ensure success in oncology. As the cost and complexity -
Early Clinical Development Solutions
Brochure — March 8, 2012
As the leader in clinical development services, with experience in more than 1,000 first-in-human and exploratory medical studies, Quintiles understands the intricacies of Phase 1/11a trials and decision making. -
Establishment and Operation of Clinical Endpoint Committees
White Paper — February 29, 2012
This white paper provides a detailed account of the operation of Clinical Endpoint Committees. It discusses how they are formed, how information is sent to -
Centralised Endpoint Adjudication in Cardiovascular Outcome Studies
Hear from the Experts — February 29, 2012
This paper provides a succinct overview of Clinical Endpoint Committees, their role in the independent adjudication of suspected cardiovascular events during clinical trials, and the need for their employment in clinical development programs for new antidiabetic drugs for Type 2 Diabetes Mellitus. -
Cardiovascular Safety Watch - Part 2: Regulatory Landscape for Off-Target Blood Pressure Assessment
Hear from the Experts — February 29, 2012
This column provides further discussion related to a potential future regulatory landscape for the assessment of off-target drug-induced blood pressure responses, based on feedback from additional cardiovascular safety conferences. -
Cardiovascular Safety Watch - DIA Cardiac and Cardiovascular Safety Conferences
Hear from the Experts — February 29, 2012
This column reviews the 2nd DIA Cardiac Safety Conference in Japan (held September 5th and 6th in Tokyo), and previews the 5th DIA European Cardiovascular Safety Conference, held on November 3rd and 4th in Barcelona. -
Cardiovascular Safety Watch - Regulatory Landscape for Off-Target Blood Pressure Assessment
Hear from the Experts — February 29, 2012
This column discusses a potential future regulatory landscape for the assessment of off-target drug-induced blood pressure responses, and the challenges of deciding which parameter(s) to focus upon, and how to determine thresholds of regulatory concern.
